Metabolism - Clinical and Experimental
Volume 44 , Pages 12-17 , October 1995

Insulin-like growth factor binding proteins as glucoregulators

  • Robert C. Baxter

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Robert C. Baxter, DSc, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.

References 

  1. Baxter RC. The insulin-like growth factors and their binding proteins. Comp Biochem Physiol. 1988;91B:229–235
  2. Krett NL, Heaton JH, Gelehrter TD. Mediation of insulin-like growth factor actions by the insulin receptor in H-35 rat hepatoma cells. Endocrinology. 1987;120:483–490
  3. Menuelle P, Plas C. Glycogenic effect of insulin, insulin-like growth factors II and I and association to their specific receptors in cultured foetal rat hepatocytes. Endocrine J. 1993;1:527–533
  4. Ballard FJ, Walton PE, Dunshea FR, et al.  Does IGF-I ever act through the insulin receptor?. In:  Baxter RC,  Gluckman PD,  Rosenfeld RG editor. The Insulin-Like Growth Factors and Their Regulatory Proteins. Amsterdam, The Netherlands: Excerpta Medica ICS; 1994;p. 131–138
  5. Schmitz F, Hartmann H, Stümpel F, et al.  In vivo metabolic action of insulin-like growth factor I in adult rats. Diabetologia. 1991;34:144–149
  6. Guler H-P, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med. 1987;317:137–140
  7. Kerr D, Tamborlane WV, Rife F, et al.  Effect of insulin-like growth factor-1 on the responses to and recognition of hypoglycemia in humans. J Clin Invest. 1993;91:141–147
  8. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, et al.  Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest. 1992;90:2234–2241
  9. Cheetham TD, Clayton KL, Holly JM, et al.  In vivo use of recombinant human IGF-I: Studies in type 1 diabetes. In:  Baxter RC,  Gluckman PD,  Rosenfeld RG editor. The Insulin-Like Growth Factors and Their Regulatory Proteins. Amsterdam, The Netherlands: Excerpta Medica ICS; 1994;p. 437–448
  10. Kuzuya H, Matsuura N, Sakamoto M, et al.  Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes. 1993;42:696–705
  11. Drop SLS, Schuller AGP, Lindenbergh-Kortleve DJ, et al.  Structural aspects of the IGFBP family. Growth Regul. 1992;2:69–79
  12. Martin JL, Baxter RC. Insulin-like growth factor binding protein-3: Biochemistry and physiology. Growth Regul. 1992;2:88–99
  13. Baxter RC. Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex. J Clin Endocrinol Metab. 1988;67:265–272
  14. Guler H-P, Zapf J, Schmid C, et al.  Insulin-like growth factors I and II in healthy man. In: Estimations of half-lives and production rates. ed 2. Acta Endocrinol (Copenh). 121:1989;p. 753–758
  15. Takada M, Nakanome H, Kishida M, et al.  Measurement of free insulin-like growth factor-I using immunoradiometric assay. J Immunoassay. 1994;15:263–276
  16. Frystyk J, Skjaerbaek C, Dinesen B, et al.  Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett. 1994;348:185–191
  17. Lewitt MS, Saunders H, Baxter RC. Bioavailability of insulin-like growth factors (IGFs) in rats determined by the molecular distribution of human IGF-binding protein-3. Endocrinology. 1993;133:1797–1802
  18. Baxter RC, Martin JL, Beniac VA. High molecular weight insulin-like growth factor binding protein complex. In: Purification and properties of the acid-labile subunit from human serum. ed 2. J Biol Chem. 264:1989;p. 11843–11848
  19. Binoux M, Hossenlopp P. Insulin-like growth factor (IGF) and IGF-binding proteins: Comparison of human serum and lymph. J Clin Endocrinol Metab. 1988;67:509–514
  20. Hodgkinson SC, Moore L, Napier JR, et al.  Characterization of insulin-like growth factor binding proteins in ovine tissue fluids. J Endocrinol. 1989;120:429–438
  21. Baxter RC, Martin JL. Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma. J Clin Invest. 1986;78:1504–1512
  22. Baxter RC. Circulating levels and molecular distribution of the acid-labile (α) subunit of the high molecular weight insulin-like growth factor-binding protein complex. J Clin Endocrinol Metab. 1990;70:1347–1353
  23. Baxter RC, Hizuka N, Takano K, et al.  Responses of insulin-like growth factor binding protein-1 (IGFBP-1) and the IGFBP-3 complex to administration of insulin-like growth factor-I. Acta Endocrinol (Copenh). 1993;128:101–108
  24. Hossenlopp P, Segovia B, Lassarre C, et al.  Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150K complex during pregnancy. J Clin Endocrinol Metab. 1990;71:797–805
  25. Davies SCC, Wass JAH, Ross RJM, et al.  The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. J Endocrinol. 1991;130:469–473
  26. Davenport ML, Isley WL, Pucilowska JB, et al.  Insulin-like growth factor-binding protein-3 proteolysis is induced after elective surgery. J Clin Endocrinol Metab. 1992;75:590–595
  27. Gargosky SE, Owens PC, Walton PE, et al.  Most of the circulating insulin-like growth factors-I and -II are present in the 150 kDa complex during human pregnancy. J Endocrinol. 1991;131:491–497
  28. Suikkari AM, Baxter RC. Insulin-like growth factor binding protein-3 is functionally normal in pregnancy serum. J Clin Endocrinol Metab. 1992;74:177–183
  29. Zapf J. Role of insulin-like growth factor II and IGF binding proteins in extrapancreatic tumor hypoglycemia. Horm Res. 1994;42:20z26
  30. Shapiro ET, Bell GI, Polonsky KS, et al.  Tumor hypoglycemia: Relationship to high molecular weight insulin-like growth factor-II. J Clin Invest. 1990;85:1672–1679
  31. Daughaday WH, Trivedi B, Baxter RC. Serum “big” insulinlike growth factor-II from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing. In: ed 2. Proc Natl Acad Sci USA. 90:1993;p. 5823–5827
  32. Baxter RC, Daughaday WH. Impaired formation of the ternary insulin-like growth factor binding protein complex in patients with hypoglycemia due to non-islet cell tumors. J Clin Endocrinol Metab. 1991;73:696–702
  33. Teale JD, Blum WF, Marks V. Alleviation of non-islet cell tumour hypoglycaemia by growth hormone therapy is associated with changes in IGF binding protein-3. Ann Clin Biochem. 1992;29:314–323
  34. Teale JD, Baxter RC, Marks V. Therapeutic GH increases IGFBP-3 ternary complex formation in cases of non-islet cell tumour hypoglycaemia. J Endocrinol. 1993;137:P53; (suppl, abstr)
  35. Hunter SJ, Daughaday WH, Callender ME, et al.  A case of hepatoma associated with hypoglycaemia and overproduction of IGF-II (E-21): Beneficial effects of treatment with growth hormone and intrahepatic adriamycin. Clin Endocrinol (Oxf). 1994;41:397–401
  36. Holman S, Corbould A, Braund W, et al.  Regulation of insulin-like growth factors and their binding proteins in non-islet cell tumour hypoglycemia. In: ed 2. Proc Endocr Soc Aust. 37:1994;p. 104; (abstr)
  37. Yeoh SJ, Baxter RC. Metabolic regulation of the growth hormone independent insulin-like growth factor binding protein in human plasma. Acta Endocrinol (Copenh). 1988;119:465–473
  38. Suikkari AM, Koivisto VA, Rutanen EM, et al.  Insulin regulates the serum levels of low molecular weight insulin-like growth factor binding protein. J Clin Endocrinol Metab. 1988;66:266–272
  39. Brismar K, Gutniak M, Povoa G, et al.  Insulin regulates the 35 kDa IGF binding protein in patients with diabetes mellitus. J Endocrinol Invest. 1988;11:599–602
  40. Lewitt MS, Baxter RC. Inhibitors of glucose uptake stimulate the production of insulin-like growth factor-binding protein (IGFBP-1) by human fetal liver. Endocrinology. 1990;126:1527–1533
  41. Snyder DK, Clemmons DR. Insulin-dependent regulation of insulin-like growth factor-binding protein-1. J Clin Endocrinol Metab. 1990;71:1632–1636
  42. Lee PDK, Conover CA, Powell DR. Regulation and function of insulin-like growth factor-binding protein-1. In: ed 2. Proc Soc Exp Biol Med. 204:1993;p. 4–29
  43. Lewitt MS, Saunders H, Baxter RC. Regulation of rat insulin-like growth factor-binding protein-1: The effect of insulin-induced hypoglycemia. Endocrinology. 1992;131:2357–2364
  44. Quin JD, Fisher BM, MacCuish AC, et al.  Insulin-like growth factor binding protein 1 response to acute insulin induced hypoglycemia in type 1 diabetes. Clin Endocrinol (Oxf). 1994;41:225–229
  45. Lewitt MS, Baxter RC. Insulin-like growth factor-binding protein-1: A role in glucose counterregulation?. Mol Cell Endocrinol. 1991;79:C147–C152
  46. Lewitt MS, Denyer GS, Cooney GJ, et al.  Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinology. 1991;129:2254–2256
  47. Lewitt MS, Saunders H, Cooney GJ, et al.  Effect of human insulin-like growth factor-binding protein-1 on the half-life and action of administered insulin-like growth factor-1 in rats. J Endocrinol. 1993;136:253–260
  48. Oelz O, Jakob A, Froesch ER. Nonsuppressible insulin-like activity (NSILA) of human serum. Eur J Clin Invest. 1970;1:48–53

☆ Supported in part by grants from the National Health and Medical Research Council, Australia.

PII: 0026-0495(95)90215-5

Metabolism - Clinical and Experimental
Volume 44 , Pages 12-17 , October 1995

Article Tools